Cardiac Arrhythmia Related to Remdesivir in COVID-19

Background: Remdesivir has shown a positive impact on patient’s clinical improvement with COVID-19 and could represent and future viral infections. Results: 16 out of 37 patients presented bradycardia, 4 of these patients had QTc > 450 ms. Infusion for 3 days or more of infusion had a higher incidence of bradycardia (12 vs 4 patients). Overall, patients without bradycardia had a longer hospitalization (20.5 vs 15.5 days); 7 patients died, 2 of them had bradycardia. Conclusion: Our results have shown clear evidence of bradycardia after remdesivir infusion. Prospective, double-blinded, and randomized studies with an evident representative sample size with various ethnicities and races are highly needed earlier than later to establish these important findings.